Tenaya Therapeutics is a biopharmaceutical company backed by The Column Group and founded by world-leading scientists from The Gladstone Institute’s Cardiovascular Division and UT Southwestern. Tenaya is dedicated to addressing heart failure through a multipronged effort that targets the fundamental cellular pathologies present in diseased cardiac muscle and leverages cutting-edge research in cardiac regeneration, induced pluripotent stem cells, and CRISPR technologies.